Opportunities in Cancer Immunotherapy Throttle Up: George Zavoico of JonesTrading Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 24 June 2015 14:45
Biotech investors are abuzz over immune checkpoint inhibitors and T-cell therapies, but which ones do you pick? JonesTrading Institutional Services Senior Equity Analyst George Zavoico is moving rapidly to initiate coverage on some key names in this space, and is casting a wide net in hopes of catching winners.
Read more...
 
Capitalize on Comeback Stories in Micro-Cap Biotech: Joe Pantginis of ROTH Capital Partners Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 17 June 2015 18:06
The list of problems with investing in micro-cap biotech stocks begins with extreme volatility and lack of liquidity and ends with the inability to get validation from sophisticated investors who are unable to own such small companies.
Read more...
 
The Big Picture: Edison's Pooya Hemami Looks Beyond Cancer for Biotech Winners Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 10 June 2015 19:16
Analyst Pooya Hemami of Edison Investment Research casts a wide net when it comes to investment opportunities in the life sciences. You name it, his universe includes it: artificial sweeteners, blood tests, sleep aids, cancer treatments, brain health.   
Read more...
 
An Undervalued Biotech Is Testing the Cure for Cancer Now, and Chen Lin Wants In Print E-mail
By William Kent   
Wednesday, 03 June 2015 12:57
Chen Lin produces a monthly scorecard that tracks the performance of the stocks in which he invests. Every month, he reveals how he is doing in his newsletter, What Is Chen Buying? What is Chen Selling? 
Read more...
 
As Cancer Immunotherapy Turns 125, WBB Securities' Steve Brozak Ponders What Investors Can Expect from Biotech Next Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 27 May 2015 18:43
Steve Brozak sees a bubble getting larger, and he is anticipating the time when biotech stocks pull back to take a breather, like all high-flying markets ultimately do. While investors may own innovative companies with highly disruptive technologies, Brozak insists on careful diligence to find names with the potential for explosive growth and avoid the disappearing acts.
Read more...
 
Exceptional Management and Disruptive Products Top the Investment Checklist for Vista Partners' Ross Silver Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 20 May 2015 15:16
Investing in micro- and small-cap biotech companies carries great risk, but for investors who take the time to dig out the value proposition, the upside can be phenomenal. Enter Ross Silver of Vista Partners, who publishes research and owns many of the stocks he writes about. In this interview with The Life Sciences Report, Silver puts two biotech names on the table for investors to consider.  
Read more...
 
Fire Up the Immune System to Fight Cancers and Boost Portfolios: John McCamant Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 13 May 2015 18:23
An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend.
Read more...
 
The Barbell Approach Builds Powerful Healthcare Stocks: StoneCastle's Bruce Campbell Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 07 May 2015 15:20
Portfolio manager Bruce Campbell wants the best of both worlds in his Canadian healthcare investments.
Read more...
 
How to Grow a Regenerative Medicine Industry in Canada: Michael May of CCRM Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 23 April 2015 12:38
There's a new kind of incubator in town. The Centre for Commercialization of Regenerative Medicine (CCRM) is a Canadian nonprofit that fosters hands-on association between academia, government, industry and investors to grow stem cell and regenerative medicine companies from the ground up. In this interview with The Life Sciences Report
Read more...
 
How to Profit from Australia's Healthiest Biotechs: Wilson HTM's Shane Storey Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 16 April 2015 12:51
Australia will always be known as a trove of natural resources, but its most precious treasure is the abundance of entrepreneurs who are all too happy to develop the country's intellectual assets.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 6 of 56

Newsletter